Immunotherapies
Total Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
110
NCT02159495
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase: Phase 1
Role: Collaborator
Start: Dec 15, 2015
Completion: Aug 6, 2026
NCT03277729
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Phase: Phase 1/2
Start: Dec 5, 2017
Completion: Nov 16, 2037
NCT04109482
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Role: Lead Sponsor
Start: Feb 17, 2020
Completion: May 17, 2023
NCT05645744
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Phase: N/A
Start: Sep 29, 2021
Completion: Apr 12, 2024
NCT05360238
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Start: May 24, 2022
Loading map...